Patents And LOEs Poised To Be Hot Q2 Topics

Novartis and Johnson & Johnson will be the first two big pharmas to release second quarter financial results, and both have faced recent patent case developments for top-selling drugs.

patent cliff
Investors want to know what to expect for upcoming patent cliffs • Source: Shutterstock

Johnson & Johnson has an opportunity to maintain the exclusivity of its top-selling drug Stelara (ustekinumab) longer than expected, while Novartis AG may be facing the opposite situation with its top-selling drug Entresto (sacubitril/valsartan). The loss of exclusivity (LOE) timelines for those drugs are essential to the companies’ sales and earnings outlooks, and investors will be anxious to get more clarity from their management teams during second quarter earnings calls.

Novartis and J&J are the first of the big pharma companies scheduled to present Q2 financial results, with Novartis slated...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.